Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast imaging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    427 result(s) found for: Breast imaging. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-007257-31 Sponsor Protocol Number: GIC/468 Start Date*: 2008-11-07
    Sponsor Name:IPOLFG
    Full Title: Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable o...
    Medical condition: large operable and locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005349-20 Sponsor Protocol Number: 2/2013 Start Date*: 2013-01-15
    Sponsor Name:Kuopio University Hospital
    Full Title: Diagnostic accuracy of contrast-enhanced ultrasound-guided axillary core biopsy in preoperative staging of the newly diagnosed invasive breast cancer - a prospective study.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001296-67 Sponsor Protocol Number: CBFU Start Date*: 2016-07-26
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: DUAL ENERGY CONTRAST ENHANCED DIGITAL MAMMOGRAPHY PERFORMANCE EVALUATION IN COMPARISON OF CONVENTIONAL DIGITAL MAMMOGRAPHY, TOMOSINTESIS AND MR IMAGING IN WOMEN FOLLOW-UP FOR BREAST CARCINOMA
    Medical condition: WOMAN WITH BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004220-34 Sponsor Protocol Number: TNPET01 Start Date*: 2012-01-19
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001587-19 Sponsor Protocol Number: UHSM0315 Start Date*: 2015-07-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk
    Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10004746 Biopsy breast normal PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10022891 - Investigations 10071224 Breast scan PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008698-69 Sponsor Protocol Number: CRAD001Y2301 Start Date*: 2009-07-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metasta...
    Medical condition: estrogen receptor positive locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed) NL (Completed) FR (Completed) BE (Completed) GB (Completed) DE (Completed) SE (Completed) ES (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003509-41 Sponsor Protocol Number: GBG90 Start Date*: 2016-08-01
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien...
    Medical condition: Patients with triple negative or HRpositive, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006109-97 Sponsor Protocol Number: TORE 20 Start Date*: 2007-02-20
    Sponsor Name:Sinikka Oksa
    Full Title: THE EFFECT OF TOREMIFENE TO THE FINDINGS OF MAGNETIC RESONANCE IMAGING IN WOMEN WITH PREMENSTRUAL MASTALGIA
    Medical condition: PREMENSTRUAL MASTALGIA
    Disease: Version SOC Term Classification Code Term Level
    8.1 10026876 Mastalgia LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012623-28 Sponsor Protocol Number: SNDX-275-0301 Start Date*: 2009-08-17
    Sponsor Name:Syndax Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer,...
    Medical condition: ER+ Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003699-38 Sponsor Protocol Number: CEDM-MRI Start Date*: 2021-04-28
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOSYNTHESIS COMPARED TO MR IMAGING WITH GADOLINIUM IN DYNAMI...
    Medical condition: Breast souspicious lesions
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066275 Comedocarcinoma of breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004613-18 Sponsor Protocol Number: MH-131 Start Date*: 2007-06-04
    Sponsor Name:BRACCO IMAGING
    Full Title: Phase III, Multicenter, Double-blind, Randomized, Crossover Study to Compare MultiHancE with MagnevisT in Contrast-Enhanced MagnetiC Resonance Imaging MRI of the BreasT. - DETECT -
    Medical condition: patiens with breast lesions which are highly suspicious or already known for malignancy which are requested for MRI
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006279 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003194-28 Sponsor Protocol Number: PULSION-001 Start Date*: 2011-10-24
    Sponsor Name:PULSION Medical Systems SE
    Full Title: Determination of the sensitivity of ICG fluorescence technique for the detection of Sentinel Lymph Nodes in breast cancer – a monocenter, prospective open-label clinical trial
    Medical condition: Breast cancer with indicated sentinel lymph node biopsy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003064-19 Sponsor Protocol Number: NeoTEC Start Date*: 2008-12-30
    Sponsor Name:Universität Leipzig
    Full Title: Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma
    Medical condition: Primary mamma carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001943-21 Sponsor Protocol Number: IFG-08-2019 Start Date*: 2021-05-14
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study
    Medical condition: Female patients with early HER2positive breast cancer, neoadjuvantly treated.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006194 Breast cancer NOS stage I LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004189-13 Sponsor Protocol Number: 1 Start Date*: 2012-02-23
    Sponsor Name:Medizinische Universität Wien
    Full Title: ASSESSMENT OF MULTIDRUG RESISTANCE IN BREAST CANCER AND LOW GRADE GLIOMA PATIENTS WITH [11C]TARIQUIDAR PET. A PILOT STUDY
    Medical condition: Prospective cohort diagnostic test accuracy study in 30 breast cancer patients scheduled for neoadjuvant chemotherapy (15 of which with Pgp-positive and 15 with Pgp-negative tumors) and 10 low grad...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10006153 Brain tumor LLT
    18.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004503-23 Sponsor Protocol Number: CS-2015-1 Start Date*: 2015-12-17
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
    Full Title: Phase II trial: uPAR-PET for preoperative staging of breast cancer patients
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013432-20 Sponsor Protocol Number: ISI2009-02 Start Date*: 2009-08-04
    Sponsor Name:Charité Campus Mitte
    Full Title: Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging
    Medical condition: Breast tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005858-23 Sponsor Protocol Number: PROMIX Start Date*: 2008-03-12
    Sponsor Name:PROMIX Trial Group
    Full Title: Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early
    Medical condition: Patients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006200 Breast cancer stage II LLT
    9.1 10006201 Breast cancer stage III LLT
    9.1 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020395-28 Sponsor Protocol Number: ARD11588(MM-121-02-02-03) Start Date*: 2011-04-14
    Sponsor Name:MERRIMACK PHARMACEUTICALS
    Full Title: Estudio de fase II, aleatorizado, doble ciego de exemestano +/- MM-121 en mujeres posmenopáusicas con cáncer de mama Her2 negativo localmente avanzado o metastásico, con receptores de estrógeno pos...
    Medical condition: cáncer de mama_____Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002714-72 Sponsor Protocol Number: GBG89 Start Date*: 2016-03-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. (GeparNuevo)
    Medical condition: Patients with triple negative, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:32:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA